Health Discovery Corporation (OTC BB: HDVY), a
biotechnology company focused on biomarker and pathway discovery for
diagnostic markers and drug targets, today announced the first meeting of
its fully constituted Scientific Advisory Board in Savannah, Georgia, USA,
from July 30 to August 1, 2004, to discuss recent biomarker discovery
successes and implement a strategy for moving these biomarkers forward
through validation and into the commercial market.
"The constituency of our Scientific Advisory Board gives me an idea of what
the manager of the 1927 Yankees, Miller Huggins, must have felt when he
looked at his roster just prior to the World Series," said Stephen D.
Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. "That
was arguably the greatest baseball team ever assembled. Among them Babe
Ruth in the year he hit 60 homers, Lou Gehrig on first base, and Waite Hoyt
pitching. It is no exaggeration to say that our Scientific Advisory Board
is the biotech equivalent of the 1927 Yankees."
"Just as the 1927 Yankees were comprised of great hitters, great fielders,
and great pitchers," Dr. Barnhill continued, "What made this group so
exceptional was the sheer quantity of individual record setting
performances and accomplishments that when combined formed a group far
ahead of it's competition. Likewise, Health Discovery Corporation's
Scientific Advisory Board, comprised of a Nobel Prize winning scientist,
world renowned physicians, internationally recognized biomarker experts,
globally experienced computer scientists and world authorities and pioneers
in mathematics, is a carefully balanced team of the leading experts in each
of the scientific disciplines essential to achieving successful
breakthroughs in bioinformatics research."
Health Discovery Corporation's Scientific Advisory Board
Herbert A. Fritsche, Jr, Ph.D., Professor and Director of Clinical
Chemistry at MD Anderson Cancer Center and a world-renowned authority on
cancer biomarkers. (Chairman)
Kary Mullis, Ph.D., Nobel Prize Recipient for his invention of PCR
(Polymerase Chain Reaction) which is hailed as one of the greatest
scientific accomplishments of the twentieth century, one that
revolutionized genetic science.
Vladimir Vapnik, Ph.D., winner of the prestigious Humboldt Research Award
and one of the world's most renowned mathematicians in the area of
statistical learning theory.
Isabelle Guyon, Ph.D., Vice-President of the International Unipen
Foundation (IUF) and an internationally recognized expert in statistical
data analysis, pattern recognition and machine learning.
Bernhard Scholkopf, Ph.D., Director at the Max Plank Institute for
Biological Cybernetics in Tubingen, Germany and a leading world authority
on pattern recognition and machine learning.
Thomas A. Stamey, M.D., Professor and the Founding Chairman of the
Department of Urology at Stanford University School of Medicine, and
considered to be the single most revered urologist and prostate cancer
expert in the world.
Ramananda K. Madyastha, M.D., Ph.D., recipient of the Raja Ravi Sher Singh
of Kalsia Memorial Cancer Research prize for outstanding contributions in
the field of cancer research.
Ken Welsh, M.D., Professor of Clinical Genomics, Royal Brompton Hospital
and Imperial College, London, England and internationally recognized for
his accomplishments in the application of modern molecular diagnostic
testing and Clinical Genomics.
Tin-Chuen Yeung, Ph.D., MBA, Pharmacologist and experienced researcher in
biotechnology; former Director of Strategy & Business Development for the
Biosciences Division at Baxter International, Inc. and now admitted to
practice patent law before the United States Patent Bar.
Dr. Barnhill stated, "The 1927 Yankees were more than the accomplishments
of each of the players. They represented TEAM in every sense of the word
and the company they shared in the dugout made these great players even
greater," Dr. Barnhill continued, "I believe this same level of success
will be accomplished when the incredible natural synergies of our TEAM of
world class scientific experts come together, face to face, with a goal of
accomplishing breakthrough scientific discoveries."
Recent Health Discovery Corporation biomarker discovery contracts include:
Health Discovery Corporation (www.healthdiscoverycorp.com) is a systems
biology oriented biomarker and pathway discovery company, which provides
any and all aspects of "First Phase" biomarker discovery. This includes
expert assessment of the clinical problem, determination of the clinical
trial set-up, the proper selection and procurement of high quality
specimens for analysis, an analytical evaluation of the specimens through
laboratory tests to produce the relevant accurate clinical data, and the
mathematical evaluation of the data using state-of-the-art computational
tools to produce an accurate identification of the important genes and
proteins and the pathways in which they interact. Health Discovery
Corporation was established to provide both pharmaceutical and diagnostic
companies with a broad range of analytical and decision support solutions
to accelerate effective diagnostic and drug discovery. Founded in
September 2003, the Company has offices in Texas, Georgia, and California.
For more information contact Robert S. Braswell IV of Health Discovery
Corporation +1-866-953-9031 or Info@healthdiscoverycorp.com.
This news release contains "forward-looking statements" within the meaning
of Section 27a of the Securities Acts of 1933 and Section 21E of the
Securities Exchange Act of 1934. Although the Company believes that the
expectations reflected in such forward-looking statements are reasonable,
it can give no assurance that such expectations will prove correct.
More information: http://www.healthdiscoverycorp.com
Contact:
Robert S. Braswell IV
Health Discovery Corporation
+1-866-953-9031
Info@healthdiscoverycorp.com